Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HealthTronics set for Endocare buy after Galil settlement

This article was originally published in Clinica

Executive Summary

HealthTronics’ acquisition of cryotherapy firm Endocare is to go ahead after the latter terminated a previously announced merger with cryotherapy company Galil Medical. Galil and Endocare settled all outstanding litigation, thus cancelling a merger deal announced in November 2008 (see Clinica No 1327, p 19). Austin, Texas-based HealthTronics will bolster its urology offering by making Endocare (Irvine, California) a wholly-owned subsidiary. As part of the deal, Endocare shareholders will have the option to exchange each share they own for either $1.35 in cash or 0.78 HealthTronics shares. This transaction was originally announced in June this year, prompting legal action from Yokneam, Israel-based Galil (see ‘Galil attempts to scupper Endocare and HealthTronics merger’, June 12 2009). Financial details of the settlement were not revealed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel